Effects of treatments on gender differences in patients with localized muscle-invasive bladder cancer

被引:0
|
作者
Zhuang, Wei [1 ]
Xie, Haiyun [1 ]
Yu, Shicheng [1 ]
Li, Yining [2 ]
Li, Gonghui [1 ]
机构
[1] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Urol, Med Sch, 3 Qingchun East Rd, Hangzhou 310016, Zhejiang, Peoples R China
[2] Fujian Med Univ, Dept Urol, Affiliated Hosp 2, 34 Zhongshan North Rd, Quanzhou 362000, Fujian, Peoples R China
关键词
Muscle-invasive bladder cancer; Gender difference; Treatment; Survival; RADICAL CYSTECTOMY; TREATMENT PATTERNS; SURVIVAL OUTCOMES; IMPACT; RISK; SEX;
D O I
10.1007/s11255-022-03200-w
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose To explore the gender differences in survival under different treatments in localized muscle-invasive bladder cancer (MIBC), and to find clinical strategies to improve the poor prognosis of female with bladder cancer (BC). Methods Patients with localized MIBC were collected in the SEER database from 2010 to 2016 to analyze the gender differences in clinical characteristics. Propensity score matching was used to balance the effects of confounding factors. Kaplan-Meier method and Cox proportional hazards regression model were performed to compare the overall survival (OS) and cancer-specific survival (CSS) of patients between different treatment subgroups. Results The entire cohort included 13,272 T2N0M0 MIBC patients, with a male-to-female incidence of 3:1. Compared with male patients, females had a higher age of onset and more blacks. There were more female patients undergoing bladder-sparing surgery (BSS) alone, and the OS and CSS were worse than those in males. The gender difference showed statistical significance in the BSS group, but not in the radical cystectomy (RC) group. Conclusion The survival of localized MIBC patients can be affected by treatments. Multi-modality treatment and RC may improve the survival prognosis of female patients.
引用
收藏
页码:1845 / 1855
页数:11
相关论文
共 50 条
  • [41] NEOADJUVANT CHEMOTHERAPY IN MUSCLE-INVASIVE BLADDER CANCER: DIFFERENCES IN CLINICAL AND PATHOLOGICAL RESPONCE
    Galosi, Andrea Benedetto
    Milanese, Giulio
    Giustini, Lucio
    Sbrollini, Giulia
    Chiodega, Isabella
    Maselli, Guevar
    Burattini, Luciano
    Berardi, Rossana
    Montironi, Rodolfo
    [J]. JOURNAL OF UROLOGY, 2017, 197 (04): : E1194 - E1195
  • [42] Organ preservation in muscle-invasive bladder cancer
    Fernando, Shaneli A.
    Sandler, Howard M.
    [J]. ONCOLOGY-NEW YORK, 2005, 19 (03): : 334 - 339
  • [43] Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer
    Singh, Amisha
    Osbourne, Appledene S.
    Koshkin, Vadim S.
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (09) : 1213 - 1230
  • [44] Actionable mutations in muscle-invasive bladder cancer
    Bambury, Richard M.
    Rosenberg, Jonathan E.
    [J]. CURRENT OPINION IN UROLOGY, 2013, 23 (05) : 472 - 478
  • [45] Muscle-Invasive Bladder Cancer and Radical Cystectomy
    Hakenberg, Oliver W.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (01) : 1 - 1
  • [46] Guideline of guidelines: Muscle-invasive bladder cancer
    Omorphos, Nicolas Pavlos
    Piedad, John Carlo Pansaon
    Vasdev, Nikhil
    [J]. TURKISH JOURNAL OF UROLOGY, 2021, 47 : S71 - S78
  • [47] Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer
    Amisha Singh
    Appledene S. Osbourne
    Vadim S. Koshkin
    [J]. Current Treatment Options in Oncology, 2023, 24 (9) : 1213 - 1230
  • [48] Perioperative immunotherapy for muscle-invasive bladder cancer
    Kim, In-Ho
    Lee, Hyo Jin
    [J]. TRANSLATIONAL ANDROLOGY AND UROLOGY, 2020, 9 (06) : 2976 - 2985
  • [49] Managing muscle-invasive bladder cancer in the elderly
    Weizer, Alon Z.
    Palella, Gaetano V.
    Montgomery, Jeffrey S.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (06) : 903 - 915
  • [50] Molecular Biomarkers in Muscle-Invasive Bladder Cancer
    Choudhury, Ananya
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 92 (04): : 705 - 706